# Pre-trial implementation study for ketamine in sickle cell disease

> **NIH NIH U24** · DUKE UNIVERSITY · 2022 · $305,888

## Abstract

Specific Aim 1: Assess healthcare stakeholders' perceptions of barriers to and facilitators for a
RCT of early administration of sub-anesthetic ketamine infusion as a pain adjunct for VOEs
using the Consolidated Framework for Implementation Research (CFRIR) and Proctor's
taxonomy for implementation outcomes. To achieve this, we will: 1A: Conduct a cross-sectional
survey study of healthcare professionals within EPPIC-Net who provide care for people with
SCD and/or provide guidance for administration of ketamine within their hospital system (i.e.,
specialties including hematology, emergency medicine, anesthesiology, and hospitalist medicine)
to assess barriers to and facilitators for the proposed RCT 1B: Conduct semi-structured
interviews of 15-20 healthcare professionals to assess barriers to and facilitators for the proposed
RCT.

## Key facts

- **NIH application ID:** 10526631
- **Project number:** 3U24NS114416-01S2
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Francis J. Keefe
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $305,888
- **Award type:** 3
- **Project period:** 2022-09-15 → 2023-08-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10526631

## Citation

> US National Institutes of Health, RePORTER application 10526631, Pre-trial implementation study for ketamine in sickle cell disease (3U24NS114416-01S2). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10526631. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*